Screener
Rigel Pharmaceuticals RIGL Debt-to-equity
Debt-to-equity at other companies
Other financials
Where this comes from
Calculated from Rigel Pharmaceuticals’s reported figures.
Based on the most recent quarter.
The source filing: Rigel Pharmaceuticals’s 10-Q, filed May 5, 2026. Open the filing →
- Filed
- May 5, 2026, 4:05 PM EDT
- Fiscal quarter
- Q4 FY2026
- Calendar quarter
- Q4 2026
- Accession
- 0001034842-26-000032
FAQ
- What is Rigel Pharmaceuticals's debt-to-equity?
- Rigel Pharmaceuticals (RIGL) reported debt-to-equity of 0.2× in Q1 2026.
- How has Rigel Pharmaceuticals's debt-to-equity changed year-over-year?
- Rigel Pharmaceuticals's debt-to-equity increased by 140.5% year-over-year, from 0.1× to 0.2×.
- What is the long-term trend for Rigel Pharmaceuticals's debt-to-equity?
- Over 3 years (2020 to 2025), Rigel Pharmaceuticals's debt-to-equity has grown at a -27.8% compound annual growth rate (CAGR), from 0.6× to 0.2×.
- What does debt-to-equity mean?
- Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.
Ask your AI about Rigel Pharmaceuticals's debt-to-equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude